FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023395871> ?p ?o ?g. }

• W2023395871 endingPage "64" @default.
• W2023395871 startingPage "58" @default.
• W2023395871 abstract "Recent studies report that intracoronary administration of autologous bone marrow mononucleated cells (BM-MNCs) may improve remodeling of the left ventricle after acute myocardial infarction (AMI). Subgroup analysis suggest that early treatment between days 4 and 7 after AMI is probably most effective; however, the optimal time point of intracoronary cell administration has never been addressed in clinical trials. Furthermore, reliable clinical predictors are lacking for identifying patients who are thought to have most benefit from cellular therapy. In a multicenter trial, 192 patients with AMI successfully treated by percutaneous coronary intervention (PCI) of the infarct-related artery will be randomized in a 1:1:1 pattern to 1 control and 2 BM-MNC treatment groups. The control group will be treated with state-of-the-art medical management. The treatment groups will receive intracoronary administration of autologous BM-MNC at 5 to 7 days or 3 to 4 weeks after the initial event, respectively. Left ventricular function as well as scar size, transmural extension, and regional wall motion score will be assessed by cardiac magnetic resonance (CMR) studies at baseline and after 4 and 12 months. Fifty milliliters of bone marrow will be harvested by aspiration from the iliac crest and then carried by courier to a centralized cell processing facility. The mononucleated cell fraction will be isolated by density gradient centrifugation, washed, and resuspended in 10 mL of injection medium. The cells will be characterized by fluorescence-activated cell sorting analysis and tested for sterility and potency both “in vitro” and “in vivo.” Bone marrow MNC will then be reinfused directly in the infarct-related coronary artery. The primary end point is the change in global left ventricular (LV) ejection fraction by CMR at 4 months as compared to baseline. Comparisons will then be made between each of the prespecified therapy subgroups (early and late after AMI) and the control group. Secondary end points include change in infarct size, change in regional myocardial thickness, and wall motion at 4 and 12 months compared to baseline. Infarct extension (size and transmural extension), time delay to PCI, and coronary flow characteristics after PCI will be assessed as potential predictors of LV remodeling and change after cell therapy. Major adverse cardiac events (MACE) (death, myocardial infarction, coronary revascularization, rehospitalization for heart failure) will be assessed at 4, 12, and 24 months and time to MACE will be estimated. With the present study, we aim to determine the optimal time point of intracoronary administration of autologous BM-MNC after AMI on LV remodeling." @default.
• W2023395871 created "2016-06-24" @default.
• W2023395871 creator A5000190765 @default.
• W2023395871 creator A5011706820 @default.
• W2023395871 creator A5013338562 @default.
• W2023395871 creator A5023566983 @default.
• W2023395871 creator A5027177910 @default.
• W2023395871 creator A5027899852 @default.
• W2023395871 creator A5034621359 @default.
• W2023395871 creator A5043068469 @default.
• W2023395871 creator A5045293936 @default.
• W2023395871 creator A5053194091 @default.
• W2023395871 creator A5055415224 @default.
• W2023395871 creator A5055656839 @default.
• W2023395871 creator A5058359408 @default.
• W2023395871 creator A5070389994 @default.
• W2023395871 creator A5074816074 @default.
• W2023395871 creator A5078066005 @default.
• W2023395871 creator A5078302229 @default.
• W2023395871 creator A5078419873 @default.
• W2023395871 creator A5087216669 @default.
• W2023395871 creator A5087261864 @default.
• W2023395871 creator A5090532632 @default.
• W2023395871 date "2010-07-01" @default.
• W2023395871 modified "2023-09-27" @default.
• W2023395871 title "Cell-based therapy for myocardial repair in patients with acute myocardial infarction: Rationale and study design of the SWiss multicenter Intracoronary Stem cells Study in Acute Myocardial Infarction (SWISS-AMI)" @default.
• W2023395871 cites W1569560733 @default.
• W2023395871 cites W1631250427 @default.
• W2023395871 cites W1968259574 @default.
• W2023395871 cites W1980558569 @default.
• W2023395871 cites W1983889201 @default.
• W2023395871 cites W1986622667 @default.
• W2023395871 cites W2003996125 @default.
• W2023395871 cites W2009184449 @default.
• W2023395871 cites W2009485059 @default.
• W2023395871 cites W2069502665 @default.
• W2023395871 cites W2071746224 @default.
• W2023395871 cites W2080454875 @default.
• W2023395871 cites W2097077362 @default.
• W2023395871 cites W2098266872 @default.
• W2023395871 cites W2108285596 @default.
• W2023395871 cites W2110667326 @default.
• W2023395871 cites W2111486034 @default.
• W2023395871 cites W2118333950 @default.
• W2023395871 cites W2125155374 @default.
• W2023395871 cites W2125635123 @default.
• W2023395871 cites W2126830306 @default.
• W2023395871 cites W2127254052 @default.
• W2023395871 cites W2135358140 @default.
• W2023395871 cites W2144139547 @default.
• W2023395871 cites W2147657870 @default.
• W2023395871 cites W2151722542 @default.
• W2023395871 cites W2152094259 @default.
• W2023395871 cites W2162106476 @default.
• W2023395871 cites W2164506013 @default.
• W2023395871 cites W2167224581 @default.
• W2023395871 cites W2168907840 @default.
• W2023395871 cites W2330814896 @default.
• W2023395871 doi "https://doi.org/10.1016/j.ahj.2010.03.039" @default.
• W2023395871 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20598973" @default.
• W2023395871 hasPublicationYear "2010" @default.
• W2023395871 type Work @default.
• W2023395871 sameAs 2023395871 @default.
• W2023395871 citedByCount "79" @default.
• W2023395871 countsByYear W20233958712012 @default.
• W2023395871 countsByYear W20233958712013 @default.
• W2023395871 countsByYear W20233958712014 @default.
• W2023395871 countsByYear W20233958712015 @default.
• W2023395871 countsByYear W20233958712016 @default.
• W2023395871 countsByYear W20233958712017 @default.
• W2023395871 countsByYear W20233958712018 @default.
• W2023395871 countsByYear W20233958712019 @default.
• W2023395871 countsByYear W20233958712020 @default.
• W2023395871 countsByYear W20233958712021 @default.
• W2023395871 countsByYear W20233958712022 @default.
• W2023395871 countsByYear W20233958712023 @default.
• W2023395871 crossrefType "journal-article" @default.
• W2023395871 hasAuthorship W2023395871A5000190765 @default.
• W2023395871 hasAuthorship W2023395871A5011706820 @default.
• W2023395871 hasAuthorship W2023395871A5013338562 @default.
• W2023395871 hasAuthorship W2023395871A5023566983 @default.
• W2023395871 hasAuthorship W2023395871A5027177910 @default.
• W2023395871 hasAuthorship W2023395871A5027899852 @default.
• W2023395871 hasAuthorship W2023395871A5034621359 @default.
• W2023395871 hasAuthorship W2023395871A5043068469 @default.
• W2023395871 hasAuthorship W2023395871A5045293936 @default.
• W2023395871 hasAuthorship W2023395871A5053194091 @default.
• W2023395871 hasAuthorship W2023395871A5055415224 @default.
• W2023395871 hasAuthorship W2023395871A5055656839 @default.
• W2023395871 hasAuthorship W2023395871A5058359408 @default.
• W2023395871 hasAuthorship W2023395871A5070389994 @default.
• W2023395871 hasAuthorship W2023395871A5074816074 @default.
• W2023395871 hasAuthorship W2023395871A5078066005 @default.
• W2023395871 hasAuthorship W2023395871A5078302229 @default.
• W2023395871 hasAuthorship W2023395871A5078419873 @default.
• W2023395871 hasAuthorship W2023395871A5087216669 @default.
• W2023395871 hasAuthorship W2023395871A5087261864 @default.
• W2023395871 hasAuthorship W2023395871A5090532632 @default.

• next